Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GR0T
|
|||
| Former ID |
DAP001137
|
|||
| Drug Name |
Methadyl Acetate
|
|||
| Synonyms |
ALPHACETYLMETHADOL; Acemethadone; Acetilmetadol; Acetylmethadol; Acetylmethadolum; Amidolacetate; Levamethadyl; Acetilmetadol [INN-Spanish]; Acetylmethadol (INN); Acetylmethadolum [INN-Latin]; Methadyl acetate (USAN); Methadyl acetate [USAN:BAN]; N-LAMM; Race-Acetylmethadol; [6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; Benzeneethanol, beta-(2-(dimethylamino)propyl)-alpha-ethyl-beta-phenyl-, acetate (ester); Benzeneethanol, .beta.-[2-(dimethylamino)propyl]-.alpha.-ethyl-.beta.-phenyl-, acetate; (R,S)-4-Dimethylamino-1-ethyl-2,2-diphenylpentyl acetat; 1-Ethyl-4-dimethylamino-2,2-diphenylpentylacetat; 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane; 4-(Dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; 6-(Dimethylamino)-4,4-Diphenyl-3-Heptanol Acetate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Opioid dependence [ICD-11: 6C43.2Z; ICD-9: 304] | Approved | [1] | |
| Therapeutic Class |
Narcotics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H31NO2
|
|||
| Canonical SMILES |
CCC(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
|
|||
| InChI |
1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3
|
|||
| InChIKey |
XBMIVRRWGCYBTQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 509-74-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
6154503, 8157599, 10510574, 15496824, 29229004, 46505532, 47206706, 48416233, 49975473, 49975474, 49975475, 49975476, 49975477, 50064825, 57326275, 77992955, 85209477, 103429509, 103936864, 104323515, 125823202, 126408779, 126422751, 126454731, 129665034, 134338382, 134977599, 137016661, 138621358, 160964700, 179226245, 198970365, 198993294, 225077631, 226491594, 241063489, 249934655
|
|||
| ChEBI ID |
CHEBI:135491
|
|||
| SuperDrug ATC ID |
N07BC03
|
|||
| SuperDrug CAS ID |
cas=001477403
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020315. | |||
| REF 2 | Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.